NCT05509868View on ClinicalTrials.gov

Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea

PHASE3UnknownINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

December 26, 2022

Study Completion Date

December 30, 2022

Conditions
Acute Pain
Interventions
DRUG

PBK_L1704 0.35mg

The subject will receive PBK\_L1704 0.35mg/ml by PCA

DRUG

PBK_L1704 0.5mg

The subject will receive PBK\_L1704 0.5mg/ml by PCA

DRUG

Placebo

The subject will receive placebo by PCA

Trial Locations (1)

Unknown

RECRUITING

Seoul Asan medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Pharmbio Korea Co., Ltd.

INDUSTRY

NCT05509868 - Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea | Biotech Hunter | Biotech Hunter